Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

The standard treatment of patients with metastatic germ-cell tumor (GCT) relapsing after first-line chemotherapy is based on a cisplatin and ifosfamide-containing three-drug regimen, which usually yields a complete response (CR) rate

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-05, Vol.25 (5), p.987-991
Hauptverfasser:	Fizazi, K., Gravis, G., Flechon, A., Geoffrois, L., Chevreau, C., Laguerre, B., Delva, R., Eymard, J.C., Rolland, F., Houede, N., Laplanche, A., Burcoveanu, D., Culine, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer chemotherapy Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Administration Schedule gemcitabine germ-cell tumor Humans Ifosfamide - administration & dosage Kaplan-Meier Estimate Life Sciences Lymphatic Metastasis Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Recurrence, Local - drug therapy Neoplasms, Germ Cell and Embryonal - drug therapy Neoplasms, Germ Cell and Embryonal - mortality Neoplasms, Germ Cell and Embryonal - secondary Pharmacology. Drug treatments Prospective Studies salvage Salvage Therapy Testicular Neoplasms - drug therapy Testicular Neoplasms - mortality Testicular Neoplasms - pathology Treatment Outcome Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The standard treatment of patients with metastatic germ-cell tumor (GCT) relapsing after first-line chemotherapy is based on a cisplatin and ifosfamide-containing three-drug regimen, which usually yields a complete response (CR) rate
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdu099